News
-
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024
Heidelberg Pharma AG to present promising new clinical data on lead ADC-candidate HDP-101 at ASH Annual Meeting 2024, showcasing potential for multiple myeloma treatment -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024
Heidelberg Pharma to present ADC candidates at scientific and financial conferences in November 2024. Updates on Amanitin-based HDP-101 and Exatecan-based HDP-201. Key targets and conference details -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024
Heidelberg Pharma AG provides insights on its operational progress and financial figures for the first nine months of fiscal year 2024. Development activities, new clinical data, R&D webinars, and guidance updates are highlighted -
